Penwest Pharmaceutical Begins Phase I Clinical Trial of PW 4153, Candidate For Treatment of Symptoms of Parkinson’s Disease

DANBURY, Conn., July 10, 2008 (PRIME NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has begun dosing in a Phase I clinical trial of PW 4153, a drug candidate for the treatment of the symptoms of Parkinson’s disease.